Patterns of Bone Mineral Density Testing in Men Receiving Androgen Deprivation for Prostate Cancer Authors
First Online: 14 May 2013 Received: 28 November 2012 Revised: 08 April 2013 Accepted: 11 April 2013 DOI:
Cite this article as: Shahinian, V.B. & Kuo, Y. J GEN INTERN MED (2013) 28: 1440. doi:10.1007/s11606-013-2477-2
Practice guidelines recommend bone mineral density (BMD) monitoring for men on androgen deprivation therapy (ADT) for prostate cancer, but single center studies suggest this is underutilized.
We examined determinants of BMD testing in men receiving ADT in a large population-based cohort of men with prostate cancer.
Retrospective cohort study.
We used the Surveillance, Epidemiology and End-Results (SEER)-Medicare database to identify 84,036 men with prostate cancer initiating ADT from 1996 through 2008.
Rates of BMD testing within the period 12 months prior to 3 months after initiation of ADT were assessed and compared to matched controls without cancer and to men with prostate cancer not receiving ADT. A logistic regression model was performed predicting use of BMD testing, adjusted for patient demographics, indications for ADT use, year of diagnosis and specialty of the physician involved in the care of the patient.
Rates of BMD testing increased steadily over time in men receiving ADT, diverging from the control groups such that by 2008, 11.5 % of men were receiving BMD testing versus 4.4 % in men with prostate cancer not on ADT and 3.8 % in the non-cancer controls. In the logistic regression model, year of diagnosis, race/ethnicity, indications for ADT use and geographic region were significant predictors of BMD testing. Patients with only a urologist involved in their care were significantly less likely to receive BMD testing as compared to those with both a urologist and a primary care physician (PCP) (odds ratio 0.71, 95 % confidence interval 0.64–0.80).
There has been a sharp increase in rates of BMD testing among men receiving ADT for prostate cancer over time, beyond rates noted in contemporaneous controls. Absolute rates of BMD testing remain low, however, but are higher in men who have a PCP involved in their care.
androgen deprivation therapy
bone mineral density
Shahinian VB, Kuo YF, Gilbert SM.
Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363:1822–1832.
Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al.
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419–24.
D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW.
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827.
Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al.
Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–2527.
Daniell HW, Dunn SR, Ferguson DW, et al.
Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181.
Wei JT, Gross M, Jaffe CA, et al.
Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999;54:607.
Diamond T, Campbell J, Bryant C, et al.
The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 1998;83:1561.
Smith M, McGovern FJ, Zietman AL, et al.
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948.
Ross RW, Small EJ.
Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002;167:1952–1956.
Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002;60(3 Suppl 1):79–85.
Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, et al.
Background to and management of treatment-related bone loss in prostate cancer. Drugs Aging. 2002;19:899–910.
Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Canc Netw. 2005;3(Suppl 1):S29–33.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS.
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164.
Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL.
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897–7903.
. NCCN clinical practice guidelines in oncology version 1.2013 prostate cancer. Last accessed March 4th, 2013.
Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005;103:237–241.
Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother. 2006;40:2107–2114.
Yee EFT, White RE, Murata GH, Handanos C, Hoffman RM.
Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Int Med. 2007;22:1305–1310.
Alibhai SMH, Yun L, Cheung AM, Paszat L.
Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA. 2012;307:255–256.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl IV):3–18.
Charlson ME, Pompei P, Ales KL, MacKenzie CR.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
Klabunde C, Potosky A, Legler J, Warren J.
Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67.
Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR.
Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458–1465.
Smith MR, Egerdie B, Toriz NH, et al.
Denusomab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–755.
Smith MR, Morton RA, Barnette KG, et al.
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184:1316–1321.
Ito K, Elkin EB, Girotra M, Morris MJ.
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med. 2010;152:621–629.
Prostate cancer: reducing fracture risk in men on androgen deprivation therapy. Nat Rev Urol. 2011;8:9–10.
King AB, Fiorentino DM.
Medicare payment cuts for osteoporosis testing reduced use despite tests’ benefit in reducing fractures. Health Aff. 2011;30:2362–2370.
Curtis JR, Laster AJ, Becker DJ, et al.
Regional variation in the denial of reimbursement for bone mineral density testing among US Medicare beneficiaries. J Clin Densitom. 2008;11:568–574.
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS.
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615–1621.
Earle CC, Burstein HJ, Winer EP, Weeks JC.
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447–1451.
Earle CC, Breville BA.
Under use of necessary care among cancer survivors. Cancer. 2004;101:1712–1719.
Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol. 2006;24:5112–5116.
PubMed CrossRef Copyright information
© Society of General Internal Medicine 2013